olivLaw · US equity research
Kura Oncology, Inc. KURA
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
Kura Oncology is a biopharmaceutical company developing precision medicines for cancer, and its product KOMZIFTI, the first menin inhibitor approved for once-daily oral use, reached the market in November 2025. In the second quarter of 2026 net product revenue for the product reached 9.1 million dollars, an early sign that the launch could become commercially meaningful.
At the close of 04 Nov 2026, Kura Oncology, Inc. (KURA) stock was 7.61 USD (−22.98% on the day), with market capitalisation 677.0 m USD, beta 1.11, 52-week range 7.40–13.59 USD. Latest reported quarter (Q2 2026): revenue of 20.9 m USD (+36.5% YoY), net income of -68.3 m USD, diluted EPS -0.77 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 26.9
- oversold (≤ 30)
- Bollinger (20, 2)
- 8.51 – 11.16
- below the lower band · %B -0.34 · band width 27.0%
- SMA 50 / 200
- 10.94 / 9.81
- mixed trend
- MACD (12, 26, 9)
- -0.38 / -0.30
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −28.3% | −2.0% | −26.4 pp | — |
| 3 months | −17.3% | −2.2% | −15.1 pp | — |
| 6 months | −20.4% | +4.3% | −24.7 pp | — |
| Year to date | −26.8% | +10.6% | −37.3 pp | — |
| 1 year | −23.6% | +10.5% | −34.1 pp | +19.9% |
| 3 years | −15.5% | +73.7% | −89.2 pp | +31.3% |
| 5 years | −61.1% | +61.7% | −122.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 14.1 m | 15.3 m | 20.8 m | 17.3 m | 18.3 m | 20.9 m |
| Cost of revenue | — | — | — | — | — | — | 262.0 k | 243.0 k |
| Research & development | 41.7 m | 52.3 m | 56.0 m | 62.8 m | 67.9 m | 64.4 m | 65.3 m | 61.9 m |
| SG&A | — | — | 22.8 m | 25.2 m | — | — | 31.6 m | 31.8 m |
| Operating income | -59.9 m | -22.5 m | -64.7 m | -72.7 m | -80.0 m | -86.3 m | -78.8 m | -73.0 m |
| Interest expense | 412.0 k | 403.0 k | 382.0 k | 391.0 k | 393.0 k | 346.0 k | 336.0 k | 345.0 k |
| Pre-tax income | -54.4 m | -17.2 m | -57.2 m | -66.1 m | -74.1 m | -80.9 m | -73.3 m | -68.3 m |
| Income tax | — | — | 226.0 k | 0 ≈ | 0 ≈ | 71.0 k | 8.0 k | 5.0 k |
| Net income | -54.4 m | -19.2 m | -57.4 m | -66.1 m | -74.1 m | -81.0 m | -73.3 m | -68.3 m |
| Diluted EPS | -0.63 | -0.22 ≈ | -0.66 | -0.75 | -0.85 | -0.92 ≈ | -0.83 | -0.77 |
| Operating cash flow | -43.4 m ≈ | 269.1 m | -71.9 m | -28.8 m ≈ | -80.6 m ≈ | 117.3 m | -85.9 m | -62.5 m ≈ |
| Capex | 0 ≈ | 372.0 k | 292.0 k | 1.5 m ≈ | 2.6 m ≈ | 2.3 m | 128.0 k | 656.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | unavailable | unavailable | 0 | 53.9 m | 67.5 m |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | +25.2% |
| Net income | -60.4 m | -63.1 m | -89.6 m | -130.5 m | -135.8 m | -152.6 m | -174.0 m | -278.7 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | -322.9% | -412.9% |
| Free cash flow | unavailable | unavailable | -72.0 m | -105.7 m | -110.7 m | -125.0 m | 133.8 m | -70.7 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 149.1 m USD
- Financial debt
- 9.7 m USD
- Net debt
- -139.4 m USD
- Equity
- 174.1 m USD
- Total assets
- 738.4 m USD
- Debt / equity
- 0.06x
- Current ratio
- 6.06x
- ROE
- -94.8%
- ROA
- -37.2%
- FCF margin
- -104.8%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 53.9 m | 67.5 m | SEC (XBRL)· 05 Mar 2026verified |
| Research & development | 60.4 m | 84.7 m | 92.8 m | 115.2 m | 170.0 m | 251.1 m | SEC (XBRL)· 05 Mar 2026verified |
| SG&A | — | — | — | 50.6 m | 77.1 m | 120.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Operating income | — | — | -139.9 m | -165.8 m | -193.2 m | -303.6 m | SEC (XBRL)· 05 Mar 2026verified |
| Interest expense | 578.0 k | 414.0 k | 229.0 k | 1.5 m | 1.6 m | 1.5 m | SEC (XBRL)· 05 Mar 2026verified |
| Pre-tax income | — | — | -135.8 m | -152.6 m | -172.0 m | -278.4 m | SEC (XBRL)· 05 Mar 2026verified |
| Income tax | 0 | 0 | 0 | 0 | 2.0 m | 297.0 k | SEC (XBRL)· 05 Mar 2026verified |
| Net income | -89.6 m | -130.5 m | -135.8 m | -152.6 m | -174.0 m | -278.7 m | SEC (XBRL)· 05 Mar 2026verified |
| Diluted EPS | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 | SEC (XBRL)· 05 Mar 2026verified |
| Weighted average diluted shares | 53.1 m | 66.4 m | 67.0 m | 73.2 m | 86.2 m | 87.7 m | SEC (XBRL)· 05 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 325.5 m | 90.7 m | 51.8 m | 37.3 m | 224.5 m | 149.1 m | SEC (XBRL)· 05 Mar 2026verified |
| Receivables | — | — | — | — | 2.1 m | 8.8 m | SEC (XBRL)· 05 Mar 2026verified |
| Inventories | — | — | — | — | 0 | 413.0 k | SEC (XBRL)· 05 Mar 2026verified |
| Current assets | 637.3 m | 522.3 m | 446.4 m | 432.5 m | 744.8 m | 708.7 m | SEC (XBRL)· 05 Mar 2026verified |
| Property, plant & equipment, net | 2.0 m | 2.7 m | 2.5 m | 1.9 m | 1.7 m | 7.9 m | SEC (XBRL)· 05 Mar 2026verified |
| Total assets | 647.2 m | 534.1 m | 456.3 m | 448.9 m | 760.2 m | 738.4 m | SEC (XBRL)· 05 Mar 2026verified |
| Accounts payable | 2.8 m | 3.2 m | 1.5 m | 2.3 m | 1.5 m | 5.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Short-term debt | 3.0 m | — | — | — | 2.6 m | 0 | SEC (XBRL)· 05 Mar 2026verified |
| Long-term debt | 4.3 m | — | 9.2 m | 9.3 m | 6.9 m | 9.7 m | SEC (XBRL)· 05 Mar 2026verified |
| Current liabilities | 26.0 m | 22.5 m | 24.1 m | 35.3 m | 78.7 m | 117.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Total liabilities | 36.3 m | 27.4 m | 36.0 m | 51.7 m | 346.5 m | 564.2 m | SEC (XBRL)· 05 Mar 2026verified |
| Equity | 610.9 m † | 506.6 m † | 420.3 m † | 397.3 m † | 413.6 m † | 174.1 m † | SEC (XBRL)· 05 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -69.8 m | -104.6 m | -110.1 m | -124.8 m | 134.3 m | -64.1 m | SEC (XBRL)· 05 Mar 2026verified |
| Capex | 2.2 m | 1.1 m | 626.0 k | 168.0 k | 472.0 k | 6.6 m | SEC (XBRL)· 05 Mar 2026verified |
| Free cash flow | -72.0 m ≈ | -105.7 m ≈ | -110.7 m ≈ | -125.0 m ≈ | 133.8 m ≈ | -70.7 m ≈ | SEC (XBRL)· 05 Mar 2026derived |
| Investing cash flow | -99.9 m | -126.8 m | 32.6 m | 15.6 m | -101.6 m | -13.1 m | SEC (XBRL)· 05 Mar 2026verified |
| Financing cash flow | 469.3 m | -3.4 m | 38.6 m | 94.8 m | 154.4 m | 1.8 m | SEC (XBRL)· 05 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 35.4% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 677.0 m USD
Key indicators
Coverage and freshness
Score by group
35% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -241.7% | 0 (vs peers) | 29% |
| Net margin · Quality | -384.3% | 18 (vs peers) | 18% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -224.0x | 0 (on a fixed band) | 18% |
| Current ratio · Balance sheet | 4.7x | 100 (on a fixed band) | 12% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -17.3% | 0 (on a fixed band) | 24% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality7/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
KURA ONCOLOGY, INC. (KURA). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 67.5 m USD in 2025; YoY growth 25.2%; net margin -384.3%; ROE -167.7%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 4.7x
What contradicts it
- ROIC: -241.7%
- Net margin: -384.3%
- Interest coverage: -224.0x
- FCF yield: -17.3%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,325.9 bn | 45.7 | 86.1% | 31.9% | +44.7% | +31% / +138% |
| JNJJohnson & Johnson | 640.8 bn | 40.4 | 20.0% | 16.2% | +6.0% | +29% / +72% |
| ONCBeone Medicines Ltd. | 524.7 bn | 817.5 | 14.7% | 10.7% | +40.2% | +4% / +90% |
| ABBVAbbVie Inc. | 505.5 bn | 49.2 | — | 15.7% | +8.6% | +26% / +101% |
| MRKMerck & Co., Inc. | 356.9 bn | 115.6 | 7.0% | 4.8% | +1.3% | +38% / +41% |
| ABTAbbott Laboratories | 190.6 bn | 30.6 | 12.4% | 13.9% | +5.7% | −15% / +5% |
| PFEPfizer Inc | 171.0 bn | 42.7 | 4.4% | 6.3% | −1.6% | +17% / −2% |
| VRTXVertex Pharmaceuticals Inc | 134.6 bn | 34.2 | 20.8% | 30.7% | +8.9% | +22% / +50% |
| BMYBristol-Myers Squibb Company | 126.1 bn | 13.7 | 44.1% | 18.5% | −0.2% | +25% / +25% |
| TEVATeva Pharmaceutical Industries Limited | 48.9 bn | 97.6 | 6.6% | 3.6% | +4.3% | +56% / +327% |
| ZTSZoetis Inc. | 34.3 bn | 13.7 | 64.4% | 27.5% | +2.3% | −35% / −53% |
| ROIVRoivant Sciences Ltd. | 26.0 bn | — | -6.2% | -3,535.0% | −71.6% | +73% / +277% |
| UTHRUnited Therapeutics Corporation | 25.8 bn | 21.5 | 19.3% | 41.6% | +10.6% | +24% / +151% |
| RPRXRoyalty Pharma plc | 25.8 bn | 37.6 | 8.5% | 32.1% | +5.1% | +66% / +145% |
| INSMInsmed Inc | 22.9 bn | — | -72.5% | -39.9% | +66.7% | −50% / +317% |
| VTRSViatris Inc. | 21.7 bn | — | -23.6% | -23.9% | −3.0% | +77% / +106% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.4 bn | 8.1 | 126.6% | 52.8% | +65.2% | −65% / −5% |
| TGTXTg Therapeutics, Inc. | 9.4 bn | 22.5 | 100.3% | 55.2% | +87.3% | +85% / +381% |
| BLRXBioLineRx Ltd | 4.9 bn | — | -12.8% | -171.7% | −95.9% | −46% / −97% |
| AGIOAgios Pharmaceuticals, Inc. | 1.9 bn | — | -34.3% | -418.2% | +48.0% | +7% / +41% |
| SLSSELLAS Life Sciences Group, Inc. | 1.8 bn | — | -39.6% | — | −100.0% | +464% / +779% |
| SVRASavara Inc | 957.4 m | — | -105.5% | — | unavailable | −26% / +21% |
| KURAKura Oncology, Inc. | 677.0 m | — | -167.7% | -384.3% | +25.2% | −24% / −16% |
| PBYIPuma Biotechnology, Inc. | 551.8 m | 20.5 | 22.0% | 11.6% | −0.9% | +112% / +174% |
| STTKShattuck Labs, Inc. | 516.9 m | — | -39.2% | -5,256.8% | −82.5% | +145% / +163% |
1- and 3-year price returns: for KURA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Kura Oncology is a biopharmaceutical company developing precision medicines for cancer, and its product KOMZIFTI, the first menin inhibitor approved for once-daily oral use, reached the market in November 2025. In the second quarter of 2026 net product revenue for the product reached 9.1 million dollars, an early sign that the launch could become commercially meaningful.
SWOT
Strengths
- KOMZIFTI has FDA approval, once-daily oral dosing and a differentiated profile compared with other menin inhibitors, which supports adoption 1.
- The company gained a majority share of new treatment starts in its class after its first two full quarters of launch 3.
- The portfolio includes ziftomenib across several indications and darlifarnib in solid tumors, diversifying development potential 1.
Weaknesses
- The company had not previously launched a product and depends entirely on the commercial success of a single medicine 1.
- Net losses remain large, and research and sales spending exceed product revenue at this stage 3.
- The current approval is limited to monotherapy for a relatively small patient population 1.
Opportunities
- Extension into frontline treatment combined with existing standards could significantly widen the addressable market 1.
- The darlifarnib platform could generate strategic partnerships or new registration paths in solid tumors 3.
- If adoption trends continue, the company could become a leader in treating NPM1-mutated AML 3.
Threats
- Competitors could launch products that are more effective, safer or less expensive, reducing the commercial potential of the product 1.
- Reimbursement restrictions and insurer policies could limit patient access to treatment 2.
- Dependence on third-party distributors and on partner Kyowa Kirin could affect commercial execution if they fall short of expectations 1.
Risks
- Dependence on a single producthigh
The company's revenue depends entirely on the success of KOMZIFTI in the United States, and if the launch does not expand, profitability could be difficult to reach 1.
- Funding needshigh
The company holds significant cash, but losses are large and financial support also depends on collaboration payments from Kyowa Kirin to fund programs until phase 3 results 3.
- Product safety and labelingmedium
The label carries a Black Box warning for differentiation syndrome, and new safety data could change how the product may be promoted 1.
- Competition and pricingmedium
Competitors could offer lower prices or better reimbursement, which could reduce the company's market share 1.
- Execution with distribution partnerslow
The company relies on a select network of distributors and specialty pharmacies, and problems there could affect supply and patient relationships 1.
Investment thesis
What would need to be true (bull case)
- If growth in new patient starts continues in coming quarters, KOMZIFTI could strengthen its leading position in the menin inhibitor class 3.
- Long-term frontline data from the KOMET-007 study suggest high response and survival rates, which could open a much larger AML market 3.
- The darlifarnib platform could bring additional partnerships or registration paths in solid tumors, diversifying the company's sources of value 3.
What would break the thesis
- Product revenue is still small relative to losses, and the company may need additional funding if the launch slows 3.
- Competition within the menin inhibitor class and from standard therapies could limit growth, especially if reimbursement remains restricted 1.
- Results for frontline expansion depend on phase 3 studies that are not yet complete, so the benefits could be delayed or fail to materialize 1.
What to watch
- Trend in new patient starts and KOMZIFTI revenueQ3 2026
- Updated data from the KOMET-007 and KOMET-008 studies2H 2026
- Initial results of the FIT-001 study with darlifarnib and cabozantinib2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Kura Oncology, Inc. presents itself as a biopharmaceutical company dedicated to precision medicine in cancer treatment, with a portfolio of small molecules targeting cancer signaling pathways 1. The company has moved from research and development to a fully integrated commercial organization after the FDA approved in November 2025 the application for ziftomenib, marketed as KOMZIFTI, for adults with relapsed or refractory AML carrying an NPM1 mutation 1. For the first six months of 2026, KOMZIFTI net product revenue was 14.9 million dollars 2.
The strategy rests on combining targeted medicines with existing standards of care so that outcomes improve, with patients selected on the basis of disease biology 1. The company aims to use ziftomenib in earlier lines of treatment, and darlifarnib, a farnesyl transferase inhibitor, is being tested in solid tumors 1. Kura funds development from its own resources and through partnerships such as the one with Kyowa Kirin.
On the revenue side, the company records US sales of KOMZIFTI, which it shares equally with Kyowa Kirin, while collaboration revenue was 11.8 million dollars in the second quarter of 2026 3. The net loss for the same quarter was 68.3 million dollars 3.
Segments
KOMZIFTI (ziftomenib) in acute myeloid leukemia
The approved product treats adults with relapsed or refractory AML with an NPM1 mutation, where the company estimates an initial US market of 350 to 400 million dollars a year 1. The launch has grown: in the second quarter of 2026 about 115 new patients started treatment, and the company says KOMZIFTI reached a majority of new starts in the menin inhibitor class 3.
Darlifarnib and solid tumors
Darlifarnib is being evaluated with targeted therapies in solid tumors such as renal cell carcinoma and pancreatic cancer, and early phase 1 data show tumor shrinkage in 77% of response-evaluable patients 3. The company describes this as a platform that may apply to several classes of therapy, but the data remain early.
Market context
The company estimates that the total US market for relapsed, refractory and frontline AML could reach about 7 billion dollars a year 1. These estimates rest on literature, government databases and assumptions about disease prevalence and pricing, so they may differ from outcomes 1. Initially KOMZIFTI is marketed for relapsed or refractory AML, and extension into frontline use depends on ongoing trial results.
Market access appears to be advancing: the company says it has secured parity coverage for more than 95% of covered lives in the United States, but some insurers require patients to try KOMZIFTI first 2. This could support adoption if the trend holds.
Trends
- Early adoption of a new menin inhibitortailwind
Results from the first quarters suggest physicians could prefer KOMZIFTI for NPM1-mutated AML if growth in new patient starts continues 3. This is a conditional reading based on a still small number of commercial quarters.
- Coverage and reimbursementmixed
Private payors have published coverage policies, but some require patients to step through KOMZIFTI before other menin inhibitors, which may limit access to rival products while strengthening the company's position 2.
- Competition within the menin inhibitor classheadwind
Revumenib is another menin inhibitor approved by the FDA for the same indication, and competitive pressure could rise if it expands its use 1. Pricing and reimbursement may also shape market share.
- Combination therapies in frontline AMLmixed
The company's plan to combine ziftomenib with standard treatments such as venetoclax and azacitidine or 7+3 chemotherapy could expand the market if phase 3 studies confirm benefit 1. Results are expected in 2028, so the impact remains uncertain.
Competitive position
The company competes with intensive and non-intensive chemotherapy, with targeted therapies against co-occurring mutations such as IDH1, IDH2 or FLT3 inhibitors, and with revumenib, the only other approved menin inhibitor for the same indication 1. The company notes that competing products could be safer, more effective, more convenient or less expensive, which could limit KOMZIFTI's commercial potential 1.
The competitive field is dominated by large pharmaceutical and biotechnology companies, and firms developing similar or different approaches may bring new treatments to market 1. KOMZIFTI's advantage could lie in once-daily dosing and the absence of dose adjustments for other medicines, if these remain differentiating 1.
- Revumenib (REVUFORJ)
Another menin inhibitor approved by the FDA for relapsed or refractory NPM1-mutated AML and for KMT2A-rearranged acute leukemia, the main direct competitor of KOMZIFTI 1.
- Intensive and non-intensive chemotherapy
Established treatments for relapsed or refractory AML that remain well accepted in medical practice and may be preferred by physicians over newer therapies 1.
- IDH1, IDH2 and FLT3 inhibitors
Targeted therapies against mutations that can co-occur with NPM1 in AML, used as alternatives or complements to treatment 1.
- Large pharmaceutical and biotechnology companies
Numerous developers of cancer treatments, some with similar approaches and greater commercial resources, that could launch superior products 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Kura Oncology Pivots Diabetes Strategy Into $50 Million SubsidiaryYahoo Finance — News · 09 Sept 2026 · EN
- The $1.24 Billion Reason Why Kura Oncology Stock Is Up TodayYahoo Finance — News · 25 Aug 2026 · EN
- Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?Yahoo Finance — News · 25 Aug 2026 · EN
- Kura Oncology Shares Jump After CEO Buys $1.24 Million of StockYahoo Finance — News · 25 Aug 2026 · EN
SEC filings
- Current report09 Sept 2026Other events
- Current report08 Sept 2026Departure or appointment of officers
- Quarterly report12 Aug 2026
- Current report12 Aug 2026Results of operations · Financial statements and exhibits
- Current report29 Jul 2026Departure or appointment of officers
- Current report04 Jun 2026Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Quarterly report12 May 2026
- Current report12 May 2026Results of operations · Financial statements and exhibits
- Proxy statement10 Apr 2026
- Annual report05 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Kura Oncology, Inc. · 05 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Kura Oncology, Inc. · 12 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Kura Oncology, Inc. · 12 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.